Article

Evaluating the therapeutic approach in pregnancies complicated by borderline glucose intolerance: a randomized clinical trial.

Department of Obstetrics and Gynaecology, Niguarda Ca'Granda Hospital, Piazza Ospedale Maggiore 3, 201621 Milan, Italy.
Diabetic Medicine (Impact Factor: 3.06). 12/2005; 22(11):1536-41. DOI: 10.1111/j.1464-5491.2005.01690.x
Source: PubMed

ABSTRACT Most studies relating minor gestational metabolic alterations to macrosomia refer to glucose intolerance classified on the basis of the National Diabetes Data Group or previous World Health Organization diagnostic thresholds. Our aim was to evaluate the consequences of very mild forms of gestational glucose intolerance, defined by an elevated 50-g glucose challenge test followed by a normal oral glucose tolerance test, using the more restrictive Carpenter and Coustan's criteria (Borderline Gestational Glucose Intolerance, BGGI).
Three hundred BGGI women were randomly assigned to: Group A (standard management), Group B (dietary treatment and regular monitoring). A control group (C) was also considered. Newborns were classified as macrosomic, large (LGA), or small for gestational age (SGA).
The three groups were similar in age, body mass index and parity. Therapy in Group B significantly improved fasting (from 4.68 +/- 0.45 to 4.28 +/- 0.45 mmol/l) and 2-h postprandial glycaemia (from 6.01 +/- 0.57 to 5.13 +/- 0.68 mmol/l). Fasting glycaemia at delivery was significantly lower in B (4.20 +/- 0.38 mmol/l) than in A (4.84 +/- 0.45 mmol/l), and was also lower than in C (4.31 +/- 0.39 mmol/l). Significantly fewer LGA babies were born to Group B (6.0%) than Group A (14.0%) and Group C (9.1%). No difference was found in the SGA rate. The neonatal Ponderal Index was higher (P = 0.030) in group A (2.73 +/- 0.35) than in C (2.64 +/- 0.30) and B (2.64 +/- 0.24).
Even very mild alterations in glucose tolerance can result in excessive or disharmonious fetal growth, which may be prevented by simple, non-invasive therapeutic measures.

0 Bookmarks
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nutrition plays a fundamental role in fetal growth and birth outcomes.
    American Journal of Clinical Nutrition 11/2014; 100(5):1298-321. · 6.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The definition of optimal glycemic control in pregnancies affected by diabetes remains enigmatic. Diabetes phenotypes are heterogeneous. Moreover, fetal macrosomia insidiously occurs even with excellent glycemic control. Current blood glucose (BG) targets (FBG ≤95, 1-h post-prandial <140, 2 h <120 mg/dL) have improved perinatal outcomes, but arguably they have not normalized. The conventional management approach has been to replicate a pattern of glycemia in normal pregnancy. Although these patterns are lower than previously appreciated, a randomized controlled trial (RCT) has never compared current vs. lower glucose targets powered on maternal/fetal outcomes. This paper provides historical context to the current targets by reviewing evidence supporting their evolution. Using lower targets (FBG <90, 1 h <122, 2 h <110, mean BG ≤95 mg/dL) may help normalize outcomes, but phenotypic differences (type 1 vs. type 2 vs. gestational diabetes) might require different glycemic goals. There remains a critical need for well-designed RCTs to confirm optimal glycemic control that minimizes both small for and large for gestational age across pregnancies affected by diabetes.
    Current Diabetes Reports 01/2015; 15(1):565. · 3.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gestational diabetes (GD), which has a prevalence of 9%, is associated with high maternal and perinatal morbidity. Early diagnosis and treatment of maternal hyperglycemia reduce the risk of macrosomia and the associated intrapartum complications. Risk factors for GD can be identified in the first trimester from maternal history (age, obesity, previous macrosomia or GD, family history of diabetes), biochemical markers (adiponectin, sex hormone-binding globuline and others), and biophysical markers (arteriography, visceral adiposity). Risk factors for macrosomia include obesity and diabetes in the maternal history, pregnancy associated plasma protein-A and free β subunit of human chorionic gonadotropin as biochemical markers, and nuchal translucency and uterine artery Doppler as biophysical markers. Prediction models combining maternal history, biochemical and biophysical markers can achieve a detection rate of 65% and 35% for GD and macrosomia, respectively, with a false positive rate of 10%.
    Progresos de Obstetricia y Ginecología 09/2014;

Full-text

Download
77 Downloads
Available from
Jun 3, 2014